A phase i/ii escalation trial design t-rad: treatment of metastatic lung cancer with mrna-engineered t cells expressing a t cell receptor targeting human telomerase reverse transcriptase (htert)

HIGHLIGHTS

• who: Só from the University of Arkansas for Medical Sciences, United States have published the Article: A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT), in the Journal: (JOURNAL)
• what: This is the first clinical study using an hTERT specific TCR for immunotherapy and the primary objectives of the T-RAD study are safety and tolerability. Safety monitoring is the main aim of this trial and thus a power analysis is not applicable . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.